Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Schering-Plough Selects Bruker solariX

By Drug Discovery Trends Editor | June 17, 2009

Bruker Daltonics announced that the Rapid Structure Characterization Laboratory (RSCL) of the Schering-Plough Research Institute (SPRI) has selected the new solariX FTMS platform as a cutting-edge tool for structural characterization and purity assessment of pharmaceuticals under development at SPRI.

Bruker Daltonics explained that the RSCL can be tasked with solving some of the most difficult chemical structure problems encountered during drug development, as well as many day-to-day applications, that companies have for structural characterization of chemical compounds.

Dr. Gary Martin, Distinguished Fellow at Schering Plough and the leader of the RSCL, commented: “The chemical formula provided by the solariX platform for both the complete unknown, as well as pieces of the unknown compound from MSn, is pivotal information that can complement the information derived from NMR spectroscopy. Combining these data can speed the solving of complex structural problems. We look forward to using solariX in our work.”

Dr. Paul Speir, Vice President for FTMS at Bruker Daltonics, stated: “Our solariX FTMS platform offers unmatched mass resolution and flexibility, a wide variety of ionization techniques, the capability to perform MSn experiments with accurate mass measurement at each stage, and is even capable of ion-molecule reactions. All of these capabilities can be useful in solving the extremely difficult structural characterization problems that pharmaceutical scientists routinely encounter.”

Date: May 29, 2009
Source: Bruker Daltonics 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE